Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Adamax vs C-Max (Cerebrolysin variant)
An educational, source-based comparison of Adamax and C-Max (Cerebrolysin variant) — how each peptide works, what it's researched for, and what to know before going deeper.
A modified form of Semax with additional N-terminal adamantyl group. Research suggests enhanced stability and penetration across the blood-brain barrier, with amplified neurotrophic and neuroprotective effects compared to parent compound.
- Neuroprotection in acute ischemia
- Cognitive enhancement in healthy adults
- Recovery from traumatic brain injury
- • Russian-origin research; limited Western clinical data.
- • Not FDA-approved.
Concentrated neuropeptide fraction for cognitive support research.
A concentrated fraction of cerebrolysin containing specific neuropeptide sequences. Research suggests enhanced delivery of neurotrophic factors supporting synaptic maintenance and neurogenesis.
- Post-stroke cognitive recovery
- Vascular cognitive impairment
- Traumatic brain injury rehabilitation
- • Not FDA-approved in the US; approved in select countries.
- • Requires medical supervision for IV administration.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
Early-stage research; conclusions are tentative.
Early-stage research; conclusions are tentative.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| Adamax | Adamax pharmacokinetics and neuroprotection | Molecular Neurobiology | 2019 | Enhanced BBB penetration and neuroprotective efficacy versus Semax in rodent models. |
| C-Max (Cerebrolysin variant) | Concentrated neuropeptide fractions in stroke rehabilitation | Neurorehabilitation and Neural Repair | 2018 | Improved functional outcomes in post-stroke patients receiving neuropeptide therapy. |
Side-effect & safety grid
- Russian-origin research; limited Western clinical data.
- Not FDA-approved.
- Not FDA-approved in the US; approved in select countries.
- Requires medical supervision for IV administration.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
Adamax vs C-Max (Cerebrolysin variant) — Key differences
- Class: Adamax is classified as Nootropic · Neuroprotection, while C-Max (Cerebrolysin variant) is Nootropic · Neurotrophic.
- Primary research focus: Adamax — neuroprotection in acute ischemia; C-Max (Cerebrolysin variant) — post-stroke cognitive recovery.
- Tag: Cognition vs Cognition.